Ari Z.Uyanik B.S.Yigitoglu M.R.Kutlu N.Pirim I.2024-07-222024-07-22199713000144http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20692The erythrocyte glutathione reductase (GSSG-R) activity with and without FAD supplementation (Act. A and Act. B, respectively) was studied in 24 undialyzed uremic patients and 25 healthy subjects. Mean erythrocyte GSSG-R activity from normal subjects was 5.39 ± 1.43 U/g Hb (the active form). After the addition of FAD to the hemolysates, this increased to 7.79 ± 1.07 U/g Hb, an increase of 1.88 ± 0.84 U/g Hb (the inactive from) (p < 0.001). In patients with FAD supplementation, erythrocyte GSSG-R activity increased from 9.26 ± 1.19 U/g Hb to 10.06 ± 1.06 U/g Hb, an increase of 0.80 ± 0.76 U/g Hb (p < 0.01). In addition, there were significant positive correlations between the enzyme activities and plasma urea level, and negative correlations between the enzyme activities and hemoglobin concentrations in patients, but not in the controls. It was concluded that further cross-sectional in vivo studies should be made to determine whether riboflavin administration may or not be useful in preventing renal anemia.Englishflavine adenine nucleotideglutathione reductaseriboflavinadolescentadultarticleclinical articlecontrolled studyenzyme activityerythrocytefemalehumanmaleurea blood leveluremiaArticle